• News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • Subscribe newsletter
  • Search
  • Menu Menu
International Hospital
  • AI
  • Cardiology
  • Oncology
  • Neurology
  • Genetics
  • Orthopaedics
  • Research
  • Surgery
  • Innovation
  • Medical Imaging
  • MedTech
  • Obs-Gyn
  • Paediatrics

Archive for category: Corona News

Corona News

Pilot study provides promising results for use of convalescent plasma as treatment for COVID-19

, 26 August 2020/in Corona News, E-News /by 3wmedia

Chinese researchers have for the first time shown in a pilot study that the use of convalescent plasma from cured COVID-19 patients provides promising results in the treatment of others with more severe disease.
In the preprint study at medRxiv (http://doi.org/dqrs; 2020), K. Duan et al. report that the administration of a single, high-dose of neutralizing antibodies is safe and provides encouraging results with regards to the reduction of viral load and improvement of clinical outcomes.
In the study, ten severe patients confirmed by real-time viral RNA test were enrolled prospectively. One dose of 200 mL convalescent plasma (CP) derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to maximal supportive care and antiviral agents.
After CP transfusion, the level of neutralizing antibody increased rapidly up to 1:640 in five cases, while that of the other four cases maintained at a high level (1:640). All patients showed significant improvement in or complete disappearance of clinical symptoms – including fever, cough, shortness of breath, and chest pain – within 3 days.
The authors state that along with increased oxyhaemoglobin saturation – indicative of recuperating lung function – several parameters also improved, including increased lymphocyte counts and decreased C-reactive protein. Radiological examinations showed varying degrees of absorption of lung lesions within 7 days. The viral load was undetectable after transfusion in seven patients who had previous viremia. No severe adverse effects were observed.
The study shows that CP therapy could potentially improve clinical outcomes through neutralizing viremia in severe COVID-19 cases, however, the authors note that further investigation is needed in larger well-controlled trials to assess the optimal dose and time point.

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:35:292020-08-26 14:35:38Pilot study provides promising results for use of convalescent plasma as treatment for COVID-19

Biopharma companies invest $1bn in new AMR Action Fund to save collapsing antibiotic research pipeline

, 26 August 2020/in Corona News, E-News /by 3wmedia

In one of the most ambitious collaborative initiatives ever undertaken by the pharmaceutical industry, more than 20 leading biopharmaceutical companies in early July announced the launch of the AMR Action Fund, a ground-breaking partnership that aims to bring two to four new antibiotics to patients by 2030. These new treatments are urgently needed to address the rapid rise of antibiotic-resistant infections – or antimicrobial resistance (AMR).
The companies have raised so far nearly US$1 billion to support clinical research of innovative new antibiotics that address the most resistant bacteria and life-threatening infections. Through the AMR Action Fund, pharmaceutical companies will join forces with philanthropies, development banks, and multilateral organizations to strengthen and accelerate antibiotic development. The Fund will focus on urgent public health needs. It will provide much needed financial resources, as well as important technical support to help biotech companies bring novel antibiotics to patients.
The AMR Action Fund, an initiative of the international body representing the R&D pharmaceutical industry (International Federation of Pharmaceutical Manufacturers & Associations, IFPMA), was announced at simultaneous virtual launch events in Berlin, Germany, and Washington, D.C., USA, on 9 July, with a third event in Tokyo, Japan on July 10.
AMR is a looming global crisis that has the potential to dwarf COVID-19 in terms of deaths and economic costs.
Commenting on the Fund, Dr Tedros Adhanom Ghebreyesus, Director General World Health Organization, said: “AMR is a slow tsunami that threatens to undo a century of medical progress. I very much welcome this new engagement of the private sector in the development of urgently-needed antibacterial treatments. WHO looks forward to working with the AMR Action Fund to accelerate research to address this public health crisis.”
New antibiotics
The world urgently needs new antibiotics, but there are few in the pipeline because of a paradox: despite the huge societal costs of AMR, there is currently no viable market for new antibiotics. New antibiotics are used sparingly to preserve effectiveness, so in recent years, a number of antibiotic-focused biotechs have declared bankruptcy or exited this space due to the lack of commercial sustainability, resulting in the loss of valuable expertise and resources. The consequence is a huge public health need for new antibiotics, but a lack of funding available for antibiotic R&D, particularly the later stages of clinical research. This creates a “valley of death” between discovery and patient access.
“With the AMR Action Fund, the pharmaceutical industry is investing nearly US$1 billion to sustain an antibiotic pipeline that is on the verge of collapse, a potentially devastating situation that could affect millions of people around the world,” said David Ricks, Chairman and CEO of Eli Lilly and Company and President of IFPMA. “The AMR Action Fund will support innovative antibiotic candidates through the most challenging later stages of drug development, ultimately providing governments time to make the necessary policy reforms to enable a sustainable antibiotic pipeline.”
With this investment, the AMR Action Fund will be the largest collective venture ever created to address AMR. The AMR Action Fund will:

  • Invest in smaller biotech companies focused on developing innovative antibacterial treatments that address the highest priority public health needs, make a significant difference in clinical practice, and save lives.
  • Provide technical support to portfolio companies, giving them access to the deep expertise and resources of large biopharmaceutical companies, to strengthen antibiotic development, and support access and appropriate use of antibiotics.
  • Bring together a broad alliance of industry and non-industry stakeholders, including philanthropies, development banks, and multilateral organizations, and help encourage governments to create market conditions that enable sustainable investment in the antibiotic pipeline.

The Fund is expected to be operational during the fourth quarter of 2020.
For more details on the AMR Action fund, visit www.AMRactionfund.com

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:35:292020-08-26 14:35:31Biopharma companies invest $1bn in new AMR Action Fund to save collapsing antibiotic research pipeline

Psychologist urges people to accept grief and not disengage amid Covid-19 pandemic

, 26 August 2020/in Corona News, E-News /by 3wmedia

As the COVID-19 pandemic upends life as people know it, changing daily routines, limiting social interactions and shaking their sense of safety, a mental health experts from U.S. hospital Cleveland Clinic’s Mellen Center is stressing that it is perfectly acceptable to feel sad about all of it.
She points out that grief is a natural response to loss – whether it is the loss of a loved one, or the loss of a sense of normalcy.
“We are experiencing a lot of disappointment right now – in both small and big ways – and grief is going to be a factor,” says clinical health psychologist Amy Sullivan, PsyD, ABPP.
“It’s really important that we process this and stay connected to other people in safe ways,” she adds.
Regarding how people should go about dealing with all of these difficult and unexpected feelings bubbling up, she says there is no right or wrong way. However, she offers four suggestions that can help people to cope with current events.
1. Look through the lens of grief and process emotions
She says that the stages of grief can provide a helpful framework for navigating these complex emotions. Experts recognize these stages as denial, anger, bargaining, despair, and acceptance. However, these experts also know that people do not step neatly from one stage to the next in this exact order, she says.
“Grief can come in waves and change on a very regular basis. Our feelings can change on a daily, or even an hourly, basis,” she explains.
Dr. Sullivan adds it is normal to go from feeling despair one day to anger the next.
“The first thing we need to do is to recognize that it is normal to have these waves of emotions that are happening on a regular basis,” Dr. Sullivan says.
Next, she says, acknowledge the loss whether it is knowing or losing someone with COVID-19, losing jobs, missing friends or family.
“Those are all very sad, difficult things for people to manage,” Dr. Sullivan says.
“Feel what you are feeling – whether it is being overwhelmed, anxious, powerless or anything else, it can help to identify and name these emotions,” she advises.
“It can be quite powerful to sit with those feelings for a few moments – to really recognize those emotions and normalize them,” she says.
However, she advises people to set a time limit on this, suggesting they give themselves five minutes to feel that emotion, and then move on to something that they know is a positive coping skill for them.
“It is important for us to accept where our feelings are at the moment and process through them, and then move into a more positive position of acceptance,” she says.
She says this can be done by identifying their own best coping mechanisms
“This is a time when people need to become innovative and develop their own individual sense of coping that works for them during this time,” she says. Examples might include deep breathing, mindfulness exercises, journaling, talking with another person, or going for a walk.
“If it comes to a point where someone cannot handle these feelings on their own, they need to seek mental health help,” Dr. Sullivan says.
2. Fight the urge to disengage
Dr. Sullivan stresses that staying connected is a powerful tool for coping during hard times. Whether that comes in the form of video chatting or sending a good old-fashioned letter, staying in touch with family, friends, neighbours and coworkers can help people to keep a positive attitude, she says.
She adds that many trained mental and behavioural health professionals are currently seeing patients through virtual visits, so that if people are having trouble coping, this could be a solution.
3. Focus on what can be controlled
Dr. Sullivan says that when there is so much uncertainty about the future, it is easy for people to get carried away, playing out the worst-case scenarios in their heads, for example worrying about themselves or someone else getting COVID-19, or wondering if things will ever get back to normal.
“Anticipating negative events can bring a sense of anxiety or fear,” Dr. Sullivan says.
She advises that, instead of agonizing over the things that cannot be known or controlled, people should be aware of what they do have control over. For example, they can choose how much news or social media they consume in a day, and they can decide what they eat. She recommends being mindful about these choices, and focusing on staying in the present.
4. Be open to joy
Lastly, Dr. Sullivan advises people to find joy and gratitude in the small things, like a video chat with family members, or the rush of fresh air when they open a window or step outside. She adds that if they are under a lockdown order, they can find ways to appreciate the opportunity to step back from the hustle and bustle of everyday life and being home.

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:35:292020-08-26 14:35:34Psychologist urges people to accept grief and not disengage amid Covid-19 pandemic

Johnson & Johnson aims to produce a billion doses of COVID-19 vaccine

, 26 August 2020/in Corona News, E-News /by 3wmedia

Johnson & Johnson has announced the selection of a lead COVID-19 vaccine candidate on which it expects to initiate human clinical studies by September at the latest with the first batches of the vaccine available for emergency use authorization in early 2021.
In addition, the company announced the significant expansion of the existing partnership between the Janssen Pharmaceutical Companies of Johnson & Johnson and the Biomedical Advanced Research and Development Authority (BARDA).
Johnson & Johnson also said the company will rapidly scale up its manufacturing capacity with the goal of providing a global supply of more than one billion doses of the vaccine.
Through the new partnership, BARDA and Johnson & Johnson together have committed more than $1 billion of investment to co-fund vaccine research, development, and clinical testing. The company says will use its validated vaccine platform and is allocating resources, including personnel and infrastructure globally, as needed, to focus on these efforts.
BARDA is part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services.
Commenting on the initiative, Alex Gorsky, Chairman and Chief Executive Officer, Johnson & Johnson, said: “The world is facing an urgent public health crisis and we are committed to doing our part to make a COVID-19 vaccine available and affordable globally as quickly as possible. As the world’s largest healthcare company, we feel a deep responsibility to improve the health of people around the world every day. Johnson & Johnson is well positioned through our combination of scientific expertise, operational scale and financial strength to bring our resources in collaboration with others to accelerate the fight against this pandemic.”
The company’s expansion of its manufacturing capacity will include the establishment of new U.S. vaccine manufacturing capabilities and scaling up capacity in other countries. The additional capacity will assist in the rapid production of a vaccine and will enable the supply of more than one billion doses of a safe and effective vaccine globally.
Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson, said: “We are very pleased to have identified a lead vaccine candidate from the constructs we have been working on since January. We are moving on an accelerated timeline toward Phase 1 human clinical trials at the latest by September 2020 and, supported by the global production capability that we are scaling up in parallel to this testing, we expect a vaccine could be ready for emergency use in early 2021.” In addition to the vaccine development efforts, BARDA and Johnson & Johnson have also expanded their partnership to accelerate Janssen’s ongoing work in screening compound libraries, including compounds from other pharmaceutical companies. The company’s aim is to identify potential treatments against the novel coronavirus. Johnson & Johnson and BARDA are both providing funding as part of this partnership. These antiviral screening efforts are being conducted in partnership with the Rega Institute for Medical Research (KU Leuven/University of Leuven), in Belgium.

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:35:292020-08-26 14:35:38Johnson & Johnson aims to produce a billion doses of COVID-19 vaccine

Superbugs and failing drugs

, 26 August 2020/in Corona News, E-News, Editors' Picks /by 3wmedia

Bacteria that develop resistance to antibiotic drugs – superbugs – pose a major global health threat to humanity. In a concerted effort to stave off this threat, several global programmes have been established and numerous new research initiatives are being carried out. Whether they are successful is yet to be seen. International Hospital reports.
Antimicrobial or antibiotic resistance is a major emerging global health threat which continues to escalate around the world. In the EU it is responsible for around 33,000 deaths each year according to the European Commission [1] and is estimated to cost the EU EUR 1.5 billion per year in healthcare costs and productivity losses.
In the United States, the Centers for Disease Control and Prevention (CDC) estimates that more than 2.8 million antibiotic-resistant infections occur in the country each year, and more than 35,000 people die as a result [2].
In the CDC’s 2019 Antimicrobial Resistance Threats Report, Robert R. Redfield, M.D., Director of the CDC, emphasises that we should stop referring to a coming post-antibiotic era. “It’s already here,” he says. “You and I are living in a time when some miracle drugs no longer perform miracles and families are being ripped apart by a microscopic enemy. The time for action is now and we can be part of the solution.”
So, what exactly is antimicrobial resistance (AMR)? Simply put, antimicrobial resistance occurs when microorganisms – such as bacteria, viruses, fungi, protozoa and helminths (worm-like parasites) – mutate or develop a resistance gene when they are exposed to antimicrobial drugs, such as antibiotics, antifungals, antivirals, antimalarials, and antihelminthics. As a result, the drugs become ineffective and infections persist in the body, increasing the risk of morbidity and mortality as well as the spread of the disease to others.
The issue is of such global importance that a political declaration was endorsed by Heads of State at the United Nations General Assembly in New York in September 2016 signalling the world’s commitment to taking a broad, coordinated approach to address the root causes of antimicrobial resistance across multiple sectors, especially human health, animal health and agriculture.
In 2015, the World Health Organization (WHO) established the Global Antimicrobial Resistance and Use Surveillance System (GLASS) [3]. The system calls on countries to monitor and report on antibiotic resistance. The WHO noted in a report published June 1 this year, that in the past three years, participation has grown exponentially. GLASS now aggregates data from more than 64,000 surveillance sites with more than 2 million patients enrolled from 66 countries across the world. In 2018 the number of surveillance sites was 729 across 22 countries.
Hanan Balkhy, Assistant Director-General for antimicrobial resistance at WHO, explained: “The enormous expansion of countries, facilities and patients covered by the new AMR surveillance system allows us to better document the emerging public health threat of AMR.”
On the back of this data, the Organization notes that high rates of resistance among antimicrobials frequently used to treat common infections, such as urinary tract infections or some forms of diarrhoea, indicate that the world is running out of effective ways to tackle these diseases. For instance, the rate of resistance to ciprofloxacin, an antimicrobial frequently used to treat urinary tract infections, varied from 8.4% to 92.9% in 33 reporting countries.
In addition, the WHO expressed concern that the trend will further be fuelled by the inappropriate use of antibiotics during the COVID-19 pandemic. The Organization points out that evidence shows that only a small proportion of COVID-19 patients need antibiotics to treat subsequent bacterial infections and, as such, has issued guidance [4] not to provide antibiotic therapy or prophylaxis to patients with mild COVID-19 or to patients with suspected or confirmed moderate COVID-19 illness unless there is a clinical indication to do so.
Solutions
What can be done to counter AMR? Although antimicrobial resistance occurs naturally over time, usually through genetic changes, there are a number of countermeasures. Primarily, healthcare practitioners should reduce the misuse and overuse of antimicrobials which are accelerating AMR. The WHO notes, for example, that in many places, antibiotics are overused and misused in people and animals, and often given without professional oversight. Examples of misuse include when they are taken by people with viral infections like colds and flu, and when they are given as growth promoters in animals or used to prevent diseases in healthy animals.

CDC’s 2019 Antimicrobial Resistant Threats Report

The CDC’s 2019 AR Threats Report lists 18 antibiotic-resistant bacteria and fungi in three categories based on the level of concern to human health – urgent, serious, and concerning. The ‘urgent’ list includes the following five threats:
Carbapenem-resistant Acinetobacter
Carbapenem-resistant Acinetobacter cause pneumonia and wound, bloodstream, and urinary tract infections. Nearly all these infections happen in patients who recently received care in a healthcare facility. They are estimated to have caused 700 deaths in the US in 2017.
Candida auris
C. auris is an emerging multidrug-resistant yeast. It can cause severe infections and spreads easily between hospitalized patients and nursing home residents.
Clostridioides difficile
C. difficile causes life-threatening diarrhoea and colitis (an inflammation of the colon), mostly in people who have had both recent medical care and antibiotics. Estimated death per year in the US: 12,800.
Carbapenem-resistant Enterobacteriaceae (CRE)
CRE are a major concern for patients in healthcare facilities. Some Enterobacteriaceae are resistant to nearly all antibiotics, leaving more toxic or less effective treatment options. Estimated deaths in the US in 2017: 1,100.
Drug-resistant Neisseria gonorrhoeae
N. gonorrhoeae causes the sexually transmitted disease gonorrhoeae that can result in life-threatening ectopic pregnancy and infertility, and can increase the risk of getting and giving HIV.
See the report for the complete list. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:35:292020-08-26 14:35:31Superbugs and failing drugs

Sanofi and Luminostics to join forces to develop smartphone-based self-testing solution for Covid-19

, 26 August 2020/in Corona News, E-News /by 3wmedia

Sanofi and Luminostics have signed an agreement to evaluate a collaboration on a unique self-testing solution for COVID-19, using Luminostics’ innovative technology, and further adding to Sanofi’s ongoing efforts to fight the COVID-19 pandemic on multiple fronts.
Luminostics would contribute its proprietary technology for consumer-diagnostics for COVID-19 testing while Sanofi would bring its clinical research testing experience and capabilities. The goal is to provide a smartphone-based solution that eliminates the current need for healthcare professional administration or laboratory tests.
“This partnering project could lead to another important milestone in Sanofi’s fight against COVID-19. The development of a self-testing solution with Luminostics could help provide clarity to an individual – in minutes – on whether or not they are infected” says Alan Main, Executive Vice President, Head of Sanofi Consumer Healthcare.
The goal of this collaboration is to provide a consumer-based test that can detect the COVID-19 virus with high sensitivity and specificity from respiratory samples. The total time from specimen collection to results is expected in the range of 30 minutes or less. It is based on Luminostics’ unique technology that utilizes a consumer smartphone’s optics, controlled by an iOS/Android app paired with an inexpensive adapter, in combination with “glow-in-the-dark” nanochemistry and signal processing artificial intelligence.
The diagnostic platform is composed of:

  • an iOS/Android app to instruct a user on how to run the test, capture and process data to display test results, and then to connect users with a telehealth service based on the results;
  • a reusable adapter compatible with most types of smartphones; and
  • consumables for specimen collection, preparation, and processing.

During the current COVID-19 crisis it became obvious that rapid, reliable mass testing is one of the key strategies for successful containment of a pandemic outbreak. While point-of-care tests were made available relatively quickly – although not in a sufficient quantity – no over-the-counter self-testing solution is currently available. A rapid self-testing solution would come with multiple advantages, including:

  • easy access and availability to patients at thousands of points-of-sale including e-commerce;
  • no further interpersonal contact necessary to conduct the testing, thereby lowering the infection risk for patient, HCP, and laboratory staff; and
  • immediate availability of results allowing fast decision making, providing consumers both public health and out-of-pocket cost benefits.
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:35:292020-08-26 14:35:34Sanofi and Luminostics to join forces to develop smartphone-based self-testing solution for Covid-19

Vehicle manufacturers retool to help medical device industry cope with demand

, 26 August 2020/in Corona News, E-News /by 3wmedia

The German Federal Government asked domestic vehicle manufacturers to produce medical equipment, such as masks and ventilators, to help fight Covid-19.
In a statement, the Volkswagen Group announced 20 March it will be providing about 200,000 category FFP-2 and FFP-3 protective face masks for public health protection in the near future. The donation is being made in close cooperation with Federal Minister of Health Jens Spahn.
A spokesperson said the company has more than 125 industrial 3-D printers which could be repurposed to make respirators or other necessary devices, once they receive the required info.
Kathrin Schnurr, spokesperson for Daimler AG Human Resources and External Affairs Communications told International Hospital: “We have inquiries from the medical technology sector. We are currently examining how we can contribute, for example by providing 3D printers or our production expertise.
“In addition, we are in constant communication with the authorities about how and where we can help, for example to sustain the supply infrastructure.”
This follows a trend across Europe as companies unrelated to the medical-device industry offer to retool factories to help make equipment to combat the shortage of devices such as respirators and face masks.

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:35:292020-08-26 14:35:38Vehicle manufacturers retool to help medical device industry cope with demand

Thirona, taking AI from spin-off to 40 countries in 6 years

, 26 August 2020/in Corona News, E-News /by 3wmedia

Thirona, a Dutch start-up company specialising in AI to analyse medical images, is offering one of their products for free to medical imaging specialists in an effort to combat the COVID-19 pandemic. International Hospital speaks to Dr Eva van Rikxoort, the Managing Director and founder of Thirona, about the company and its products.
International Hospital: Thirona is a Dutch company established in 2014. Can you give our readers a bit of background about the company?
Eva van Rikxoort: Thirona started in 2014 as a spin-off from the Radboud University in Nijmegen. We started with two full-time employees and we have built our company to 25 full-time employees and 20 part-time medical analysists. Together, we developed artificial intelligence software to analyse chest CT scans, chest X-ray images and retina images. Healthcare specialists around the world use our AI software for diseases like asthma, COPD, tuberculosis and diabetic retinopathy.
IH: What led you to set it up?
EVR: I was doing research on chest CT analysis at the Radboud University with my co-founder Prof. Bram van Ginneken. We saw that there was a gap between research that was being done on potential clinical solutions and putting those into clinical practice; Thirona was founded with the vision to bridge that gap.
IH: What products did you have at that time?
EVR: We started with two launching customers for one solution – our AI solution for chest CT analysis.
IH: Where does the name Thirona come from?
EVR: The name Thirona comes from the Celtic goddess named Thirona, worshipped for healing. Although more commonly spelled as ‘Sirona’ in the Latin alphabet, the spelling Thirona was chosen to reflect our roots in thoracic image analysis.
IH: Delft Imaging appears to be part of Thirona. Can you tell us a bit more about Delft Imaging and the relationship between Thirona and Delft Imaging?
EVR: Technically, Thirona and Delft Imaging are separate companies, although we collaborate extensively and practically work together as sister companies. Where Thirona specialises in artificial intelligence software for medical imaging, Delft Imaging specialises in diagnostic innovations that can be used in developing countries. For example, our AI solution for chest X-ray analysis (CAD4TB) is developed by Thirona and distributed by Delft Imaging.
IH: Can you tell us briefly about your key products and where they are being used?
EVR: We essentially offer three categories of products. AI software for chest CT analysis focusing on COPD and asthma, called LungQ; AI software for X-ray analysis – focusing on tuberculosis, called CAD4TB; and AI software for the analysis of retinal images – focusing on DR, AMD and Glaucoma, called RetCAD. LungQ allows for the quantification of chest CTs and is used for patient monitoring, treatment planning and clinical trial analysis.It is mostly used across the United States and European Union. CAD4TB is used in 40 countries around the world and has screened more than 6 million people for tuberculosis. RetCAD is being rolled out across Europe and Asia.
IH: If we look at how the company has grown over the past 5-6 years — can you explain what has been the driving force behind the growth?
EVR: As a spin-off of the Radboud University, our company (and our solutions) is rooted in science. Every software product we develop is thoroughly validated (through 150+ publications to date) and that level of validation drives our growth, I believe; our customers know the type of quality we aim to offer.
IH: What guided your research and development? In other words, why did you take the product development route you have taken?
EVR: We are a demand-driven organisation. Meaning, we develop and work on where our customers and partners have needs to be supported. That has led us on the route we have been on for the past sevearl years.
IH: What are the main challenges have you faced and how have you overcome them?
EVR: One of the main challenges was keeping the same culture in the company during the growth from a small team of a few people with similar backgrounds to a larger more diverse team. We did this by installing a management team structure. By making it a focus for each team allowed us to overcome any difficulties.
IH: Most recently, you are offering a free AI-powered COVID-19 tool – the CAD4COVID-Xray. I understand it has been developed on the back of your successful TB-screening AI tool, CAD4TB. Can you explain how the CAD4TB tool works and how you adapted it for COVID-19 screening.
EVR: Yes, we developed two AI-powered COVID-19 tools actually: one for chest X-ray analysis and one for chest CT. Both have been built on the technical foundation of our existing and proven CAD4TB and LungQ solutions. Because there were underlying algorithms already in place, we were able to rapidly pivot these for the detection of COVID-19.
IH: How will this tool help healthcare facilities and COVID-19 patients?
EVR: CAD4COVID-XRay and CAD4COVID-CT automatically detect COVID-19 related abnormalities and thereby help with triage before any follow-up testing, like RT-PCR. This helps to reduce the workload of healthcare personnel and alleviate the burden on RT-PCR tests. Furthermore, both solutions show the percentage of affected lung tissue, thereby helping to track disease progress and recovery.
IH: How has the AI tool been validated? Has it been approved for use in Europe? In which other countries / regions has it been approved?
EVR: We have done several studies for both solutions (a publication on CAD4COVID-XRay was recently published in Radiology), through which we were able to prove that the software performs on par with expert human readers. For both solutions we have applied for class IIa CE certification, which we expect to receive soon.
IH: Are the CAD4COVID tools specific to certain platforms?
EVR: Both solutions are system agnostic. They process DICOM images which can be from any type of system.
IH: Are you receiving many requests for the CAD4COVID-Xray AI tool?
EVR: The response has been tremendous, which is probably also because we made the software available free-of-charge. CAD4COVIDXRay was launched first (March 31st) and has since been made available to 30+ healthcare facilities across more than 20 countries. We are especially focusing on resource-constrained settings (mostly in developing countries) because in those settings CT often has limited availability, making X-ray all the more important. CAD4COVID-CT was launched a month later and is available at 15+ facilities across 10 countries. We are also integrating it in several platforms through collaborations with partner companies like Smart Reporting.
IH: Why are you offering it for free?
EVR: We knew that for CAD4COVID to have the biggest impact during the pandemic and provide the most support to healthcare specialists globally, we needed to roll it out rapidly. In order to do that, we wanted to avoid as many hurdles as possible that could cause a delay in facilities being able to use the software. We believe cost is a big factor in that. That’s why we, supported by several organisations, have made it available to use free-of-charge.
IH: Can it be shared easily with healthcare facilities that want to use it?
EVR: Yes, people can fill in a form on www.delft.care/cad4covid (for CAD4COVID-XRay) and www.thirona.eu/cad4covid (for CAD4COVID-CT) and our team will reach out to them to help them set it up for their facility.
IH: Is any training required to use the CAD4COVID tools?
EVR: The tool is designed to be very intuitive, but we have developed an onboarding tool to guide new users on how to use the software effectively.
IH: Lastly, what’s in the pipeline for Thirona and how do you envisage development of the field of AI in medical imaging?
EVR: We are quickly expanding into other areas like cystic fibrosis on chest CT analysis, silicosis on chest X-ray analysis and cataract on retinal images. I believe that AI still has to prove itself in many settings, for many different use cases, but that it will become more and more accepted over time, and we already see this happening at incredible speed. In time, AI will leverage the efforts of our healthcare specialists, helping them to diagnose and determine treatment planning quicker, more effectively and reduce their workload in the meantime.

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:35:292020-08-26 14:35:31Thirona, taking AI from spin-off to 40 countries in 6 years

COVID-19: Mid-field lessons from the pandemic

, 26 August 2020/in Corona News, E-News /by 3wmedia
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:35:292020-08-26 14:35:36COVID-19: Mid-field lessons from the pandemic

Medtronic aims to double ventilator manufacturing capacity

, 26 August 2020/in Corona News, E-News /by 3wmedia

Medtronic said 18 March it plans to more than double its capacity to make and supply ventilators to fight the global pandemic.
Medtronic, an industry leader in respiratory care and device innovation, said that they had already increased production by more than 40 percent and were on track to more than double its capacity to manufacture and supply ventilators.
The company said it recognizes the acute need for ventilators as life-saving devices in the management of COVID-19 infections. High-performance ventilators play a critical role in the management of patients with severe respiratory illness, such as COVID-19. Without ventilation support, some patients with severe respiratory disease might not survive.
“Medtronic recognizes the demand for ventilators in this environment has far outstripped supply,” said Bob White, executive vice president and president of the Minimally Invasive Therapies Group at Medtronic. “No single company will be able to fill the current demands of global healthcare systems. However, with all manufacturers increasing their production and through partnerships with governments, hospitals and global health organizations, Medtronic is committed to getting more ventilators into the market and to the right locations in the world to help doctors and patients dealing with COVID-19.”
Medtronic produces high performance ventilators for a variety of care settings, including the acute segment (in-hospital patients in intensive care units, emergency departments or on the general care floors) and the sub-acute segment (out of hospital, long-term care facilities or home-ventilated patients).
Medtronic manufactures the Puritan Bennett 980 (PB 980) and Puritan Bennett 840 (PB 840) high performance ventilators in Galway, Ireland, which are primarily designed for critically ill patients in high acuity setting, such as some Covid-19 patients.
In the company’s Ireland ventilator manufacturing facility, the company currently has over 250 employees dedicated to ventilator manufacturing and plans to more than double that number, including transferring staff from other Medtronic sites to support ramp up activities.
Ventilator manufacturing is a complex process that relies on a skilled workforce, a global supply chain and a rigorous regulatory regime to ensure patient safety.
Medtronic said it is prioritizing high risk/high needs areas for ventilator allocation on a weekly basis for global distribution through its supply chain. Covid-19 is a dynamic global issue, and Medtronic will continue to monitor the situation.

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:35:292020-08-26 14:35:38Medtronic aims to double ventilator manufacturing capacity
Page 4 of 6«‹23456›»

Latest issue of International Hospital

April 2024

19 May 2025

Medical milestone: World’s first human bladder transplant successfully performed

16 May 2025

Mindray launches premium ultrasound system to enhance diagnostic capabilities

15 May 2025

World’s first personalised CRISPR therapy treats child with rare metabolic disorder

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The medical devices information portal connecting healthcare professionals to global vendors

Sign in for our newsletter
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Media kit
    • Submit Press Release

Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com

PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Sign in for our newsletter

Free subscription